The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Verrica Pharmaceuticals Inc (NASDAQ: VRCA) closed at $0.52 in the last session, down -10.28% from day before closing price of $0.58. In other words, the price has decreased by -$10.28 from its previous closing price. On the day, 3.89 million shares were traded. VRCA stock price reached its highest trading level at $0.5811 during the session, while it also had its lowest trading level at $0.5226.
Ratios:
We take a closer look at VRCA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 1.34.
Needham Upgraded its Hold to Buy on July 25, 2023, while the target price for the stock was maintained at $10.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 17 ’25 when Hayes Christopher G. sold 4,315 shares for $0.65 per share. The transaction valued at 2,805 led to the insider holds 176,458 shares of the business.
Hayes Christopher G. sold 26,183 shares of VRCA for $69,647 on Aug 26 ’24. The CHIEF LEGAL OFFICER now owns 115,303 shares after completing the transaction at $2.66 per share. On Aug 27 ’24, another insider, Hayes Christopher G., who serves as the CHIEF LEGAL OFFICER of the company, sold 9,530 shares for $2.46 each. As a result, the insider received 23,444 and left with 105,773 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRCA now has a Market Capitalization of 48335796 and an Enterprise Value of 61173792. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.73. Its current Enterprise Value per Revenue stands at 8.521 whereas that against EBITDA is -1.138.
Stock Price History:
The Beta on a monthly basis for VRCA is 1.79, which has changed by -0.9342138 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, VRCA has reached a high of $8.98, while it has fallen to a 52-week low of $0.38. The 50-Day Moving Average of the stock is -4.49%, while the 200-Day Moving Average is calculated to be -38.16%.
Shares Statistics:
According to the various share statistics, VRCA traded on average about 305.07K shares per day over the past 3-months and 571000 shares per day over the past 10 days. A total of 91.79M shares are outstanding, with a floating share count of 50.08M. Insiders hold about 45.85% of the company’s shares, while institutions hold 31.92% stake in the company. Shares short for VRCA as of 1749772800 were 2968309 with a Short Ratio of 9.73, compared to 1747267200 on 3153844. Therefore, it implies a Short% of Shares Outstanding of 2968309 and a Short% of Float of 5.7800002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Verrica Pharmaceuticals Inc (VRCA) in the stock market.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.06 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.26 and -$0.45 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.24, with 3.0 analysts recommending between -$0.24 and -$0.25.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $4.37M. It ranges from a high estimate of $5.1M to a low estimate of $3M. As of the current estimate, Verrica Pharmaceuticals Inc’s year-ago sales were $5.18MFor the next quarter, 3 analysts are estimating revenue of $5.63M. There is a high estimate of $7M for the next quarter, whereas the lowest estimate is $4M.
A total of 4 analysts have provided revenue estimates for VRCA’s current fiscal year. The highest revenue estimate was $25.4M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $19.62M. In the same quarter a year ago, actual revenue was $7.57MBased on 3 analysts’ estimates, the company’s revenue will be $34.57M in the next fiscal year. The high estimate is $50M and the low estimate is $23.7M.
